최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Biomedicines, v.10 no.11, 2022년, pp.2690 -
Park, Sun Young (College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon 16499, Korea) , Chung, Ye Seo (Department of Biohealth Regulatory Science, Graduate School of Ajou University, Suwon 16499, Korea) , Park, So Yeon (Department of Biohealth Regulatory Science, Graduate School of Ajou University, Suwon 16499, Korea) , Kim, So Hee (College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon 16499, Korea)
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In this study, oxaliplatin-resistant (OR) colorectal cancer (CRC) cells of HCT116, HT29, SW480 and SW6...
1. Xi Y. Xu P. Global colorectal cancer burden in 2020 and projections to 2040 Transl. Oncol. 2021 14 101174 10.1016/j.tranon.2021.101174 34243011
2. Parkin D.M. Bray F. Ferlay J. Pisani P. Global cancer statistics, 2002 CA Cancer J. Clin. 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
3. Andre N. Schmiegel W. Chemoradiotherapy for colorectal cancer Gut 2005 54 1194 1202 10.1136/gut.2004.062745 16009693
4. Gustavsson B. Carlsson G. Machover D. Petrelli N. Roth A. Schmoll H. Tveit K. Gibson F. A review of the evolution ofsystemic chemotherapy in the management of colorectal cancer Clin. Color. Cancer 2015 14 1 10 10.1016/j.clcc.2014.11.002
5. Housman G. Byler S. Heerboth S. Lapinska K. Longacre M. Snyder N. Sarkar S. Drug resistance in cancer: An overview Cancers 2014 6 1769 1792 10.3390/cancers6031769 25198391
6. Bao L. Hazari S. Mehra S. Kaushal D. Moroz K. Dash S. Increased expression of P-glycoprotein and doxorubicinchemoresistance of metastatic breast cancer is regulated by miR-298 Am. J. Pathol. 2012 180 2490 2503 10.1016/j.ajpath.2012.02.024 22521303
7. Yuan Z. Shi X. Qi Y. Jia T. Yuan X. Zou Y. Liu C. Yu H. Yuan Y. He X. Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin Oncol. Rep. 2017 37 1815 1825 10.3892/or.2017.5410 28184922
9. Chao D. Jiao W. Yin C. Jianyun N. Ceshi C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer Front. Pharmacol. 2021 12 628690 33790792
10. Guerrero-Zotano A. Mayer I.A. Arteaga C.L. PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment Cancer Metastasis Rev. 2016 35 515 524 10.1007/s10555-016-9637-x 27896521
12. Zou Z. Tao T. Li H. Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges Cell Biosci. 2020 10 10 31 10.1186/s13578-020-00396-1 32025281
13. Sarbassov D.D. Ali S.M. Sabatini D.M. Growing roles for the mTOR pathway Curr. Opin. Cell Biol. 2005 17 596 603 10.1016/j.ceb.2005.09.009 16226444
14. Heras-Sandoval D. Pérez-Rojas J.M. Hernández-Damián J. Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway inthe modulation of autophagy and the clearance of protein aggregates in neurodegeneration Cell Signal. 2014 26 2694 2701 10.1016/j.cellsig.2014.08.019 25173700
15. Roper J. Richardson M.P. Wang W.V. Richard L.G. Chen W. Coffee E.M. Sinnamon M.J. Lee L. Chen P. Bronson R.T. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model ofPIK3CA wild-type colorectal cancer PLoS ONE. 2011 6 e25132 10.1371/journal.pone.0025132 21966435
16. Kondo Y. Kanzawa T. Sawaya R. Kondo S. The role of autophagy in cancer development and response to therapy Nat. Rev. Cancer 2005 5 726 734 10.1038/nrc1692 16148885
17. Li W. Zhou Y. Yang J. Li H. Zhang H. Zheng P. Curcumin induces apoptotic cell death and protective autophagy in human gastric cancer cells Oncol. Rep. 2017 37 3459 3466 10.3892/or.2017.5637 28498433
18. Wang Z. Wang N. Liu P. Xie X. AMPK and cancer Exp. Suppl. 2016 107 203 226 27812982
19. Zhang D. Wang W. Sun X. Xu D. Wang C. Zhang Q. Wang H. Luo W. Chen Y. Chen H. AMPK regulates autophagyby phosphorylating BECN1 at threonine 388 Autophagy 2016 12 1447 1459 10.1080/15548627.2016.1185576 27304906
20. Cao Z. Yang Y. Yu S. Li Y. Wang W. Huang J. Xie X. Xiong L. Lei S. Peng C. Pogostone induces autophagy andapoptosis involving PI3K/akt/mTOR axis in human colorectal carcinoma HCT116 cells J. Ethnopharmacol. 2017 202 20 27 10.1016/j.jep.2016.07.028 27416805
21. Vander Heiden M.G. Cantley L.C. Thompson C.B. Understanding the warburg effect: The metabolic requirements of cellproliferation Science 2009 324 1029 1033 10.1126/science.1160809 19460998
22. Suh D.H. Kim M.A. Kim H. Kim M. Kim H.S. Chung H.H. Kim Y. Song Y.S. Association of overexpression of hexokinase IIwith chemoresistance in epithelial ovarian cancer Clin. Exp. Med. 2013 14 345 353 10.1007/s10238-013-0250-9 23949336
23. Peng J. Cui Y. Xu S. Wu X. Huang Y. Zhou W. Wang S. Fu Z. Xie H. Altered glycolysis results in drug-resistant inclinical tumor therapy Oncol. Lett. 2021 21 1 14 10.3892/ol.2021.12630 33240407
24. Wang G. Yu Y. Wang Y.Z. Yin P.H. Xu K. Zhang H. The effects and mechanisms of isoliquiritigenin loaded nanoliposomes regulated AMPK/mTOR mediated glycolysis in colorectal cancer Artif. Cells Nanomed. Biotechnol. 2020 48 1231 1249 10.1080/21691401.2020.1825092 32985258
25. Bleiberg H. Oxaliplatin (L-OHP): A new reality in colorectal cancer Br. J. Cancer 1998 77 1 3 10.1038/bjc.1998.427
26. Perego P. Robert J. Oxaliplatin in the era of personalized medicine: From mechanistic studies to clinical efficacy Cancer Chemother. Pharmacol. 2016 77 5 18 10.1007/s00280-015-2901-x 26589793
27. Chen W. Lian W. Yuan Y. Li M. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress Cell Death Dis. 2019 10 600 10.1038/s41419-019-1824-6 31395855
28. Seetharam R.N. Sood A. Goel S. Oxaliplatin: Pre-clinical perspectives on the mechanisms of action, response and resistance Ecancermedicalscience 2009 3 153 22276017
29. Martinez-Balibrea E. Martínez-Cardús A. Ginés A. Ruiz de Porras V. Moutinho C. Layos L. Manzano J.L. Bugés C. Bystrup S. Esteller M. Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance Mol. Cancer Ther. 2015 14 1767 1776 10.1158/1535-7163.MCT-14-0636 26184483
30. Noordhuis P. Laan A.C. Van de Born K. Honeywell R.J. Peters G.J. Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines Int. J. Mol. Sci. 2019 20 3619 10.3390/ijms20153619 31344863
31. Sun W. Ge Y. Cui J. Yu Y. Liu B. Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatmentthrough inhibition of PKM2 Mol. Ther. Oncolytics. 2021 21 87 97 10.1016/j.omto.2021.03.010 33981825
32. Yin C. Lu W. Ma M. Yan Q. He W. Hu Y. Xia L. Efficacy and mechanism of combination of oxaliplatin with PKM2knockdown in colorectal cancer Oncol. Lett. 2020 20 312 10.3892/ol.2020.12175 33093921
33. Sun X. Hou W. Liu X. Chai J. Guo H. Yu J. Targeting REV7 efectively reverses 5-FU and oxaliplatin resistance in colorectalcancer Cancer Cell. Int. 2020 20 580 10.1186/s12935-020-01668-z 33292253
35. Yoo H.Y. Park S.Y. Chang S.Y. Kim S.H. Regulation of butyrate-induced resistance through AMPK signaling pathway in humancolon cancer cells Biomedicines 2021 9 1604 10.3390/biomedicines9111604 34829834
36. Meyer G. Czompa A. Reboul C. Stepania E. Czegledi A. Bak I. Balla G. Balla J. Tosaki A. Lekli I. The cellular autophagymarkers beclin-1 and LC3B-II are increased during reperfusion in fibrillated mouse hearts Curr. Pharm. Des. 2013 19 6912 6918 10.2174/138161281939131127122510 23590156
37. Cao W. Li J. Yang K. Cao D. An overview of autophagy: Mechanism, regulation and research progress Bull. Cancer 2021 108 304 322 10.1016/j.bulcan.2020.11.004 33423775
38. Tanida I. Ueno T. Kominami E. LC3 and Autophagy Methods Mol. Biol. 2008 445 77 88 18425443
39. Woynarowski J.M. Faivre S. Herzig M.C. Arnett B. Chapman W.G. Trevino A.V. Raymond E. Chaney S.G. Vaisman A. Varchenko M. Oxaliplatin-induced damage of cellular DNA Mol. Pharmacol. 2000 58 920 927 10.1124/mol.58.5.920 11040038
40. Teng R. Hu Y. Zhou J. Seifer B. Chen Y. Shen J. Wang L. Overexpression of Lin28 decreases the chemosensitivity of gastriccancer cells to oxaliplatin, paclitaxel, doxorubicin, and fluorouracil in part via microRNA-107 PLoS ONE 2015 10 e0143716 10.1371/journal.pone.0143716 26636340
41. Kang H.R. Choi H.G. Jeon C.K. Lim S. Kim S.H. Butyrate-mediated acquisition of chemoresistance by human colon cancercells Oncol. Rep. 2016 36 1119 1126 10.3892/or.2016.4838 27277338
42. Barrasa J.I. Santiago-Gómez A. Olmo N. Lizarbe M.A. Turnay J. Resistance to butyrate impairs bile acid-induced apoptosisin human colon adenocarcinoma cells via up-regulation of bcl-2 and inactivation of bax. Biochim Biophys. Acta Mol. Cell Res. 2012 1823 2201 2209 10.1016/j.bbamcr.2012.08.008 22917577
43. Derjuga A. Richard C. Crosato M. Wright P.S. Chalifour L. Valdez J. Barraso A. Crissman H.A. Nishioka W. Bradbury E.M. Expression of p21Waf1/Cip1 and cyclin D1 is increased in butyrate-resistant HeLa cells J. Biol Chem. 2001 276 37815 37820 10.1074/jbc.M104735200 11477082
44. Shi Q. Li Y. Li S. Jin L. Lai H. Wu Y. Cai Z. Zhu M. Li Q. Li Y. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer Nat. Commun. 2020 11 5513 10.1038/s41467-020-19349-w 33139730
46. Zhao Y. Hu X. Liu Y. Dong S. Wen Z. He W. Zhang S. Huang Q. Shi M. ROS signaling under metabolic stress: Cross-talk between AMPK and AKT pathway Mol. Cancer 2017 16 1 12 10.1186/s12943-017-0648-1 28093071
47. Arciuch V.G.A. Russo M.A. Kang K.S. Cristofano A.D. Inhibition of AMPK and Krebs cycle gene expression drives metabolicremodeling of Pten-deficient preneoplastic thyroid cells Cancer Res. 2013 73 5459 5472 10.1158/0008-5472.CAN-13-1429 23796563
48. Vucicevic L. Misirkic M. Kristina J. Vilimanovich U. Sudar E. Isenovic E. Prica M. Harhaji-Trajkovic L. Kravic-Stevovic T. Vladimir B. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independentblockade of akt/mTOR pathway Autophagy 2011 7 40 50 10.4161/auto.7.1.13883 20980833
49. Lee S. Yang W. Kim D.K. Kim H. Shin M. Choi K.U. Suh D.S. Kim Y.H. Hwang T.-H. Kim J.H. Inhibition of MEK-ERKpathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer Mol. Ther. Oncolytics 2022 25 211 224 10.1016/j.omto.2022.04.006 35592390
50. Wu C. Chao Y. Shiah S. Lin W. Nutrient deprivation induces the warburg effect through ROS/AMPK-dependent activation ofpyruvate dehydrogenase kinase Biochim. Biophys Acta Mol. Cell Res. 2013 1833 1147 1156 10.1016/j.bbamcr.2013.01.025
51. Mouradian M. Kikawa K.D. Dranka B.P. Komas S.M. Kalyanaraman B. Pardini R.S. Docosahexaenoic acid attenuatesbreast cancer cell metabolism and the warburg phenotype by targeting bioenergetic function Mol. Carcinog. 2014 54 810 820 10.1002/mc.22151 24729481
52. Gharibpoor F. Zonouzi S.K. Razi S. Rezaei H. AMPK’s double-faced role in advanced stages of prostate cancer Clin. Transl. Oncol. 2022 24 2064 2073 10.1007/s12094-022-02874-z 35781781
53. Yao Z. Xie F. Li M. Liang Z. Xu W. Yang J. Liu C. Li H. Zhou H. Qu L.-H. Oridonin induces autophagy via inhibition ofglucose metabolism in p53-mutated colorectal cancer cells Cell Death Dis. 2017 8 e2633 10.1038/cddis.2017.35 28230866
54. Catanzaro D. Gabbia D. Cocetta V. Biagi M. Ragazzi E. Montopoli M. Carrara M. Silybin counteracts doxorubicin resistanceby inhibiting GLUT1 expression Fitoterapia 2018 124 42 48 10.1016/j.fitote.2017.10.007 29031537
55. Cao X. Fang L. Gibbs S. Huang Y. Dai Z. Wen P. Zheng X. Sadee W. Sun D. Glucose uptake inhibitor sensitizes cancercells to daunorubicin and overcomes drug resistance in hypoxia Cancer Chemother. Pharmacol. 2007 59 495 505 10.1007/s00280-006-0291-9 16906425
56. Mendoza E.E. Pocceschi M.G. Kong X. Leeper D.B. Caro J. Limesand K.H. Burd R. Control of glycolytic flux by AMP-activatedprotein kinase in tumor cells adapted to low pH Transl. Oncol. 2012 5 208 216 10.1593/tlo.11319 22741040
57. Domenech E. Maestre C. Esteban-Martínez L. Partida D. Pascual R. Fernandez-Miranda G. Seco E. Campos-Olivas R. Perez M. Megias D. AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest Nat. Cell Biol. 2015 17 1304 1316 10.1038/ncb3231 26322680
※ AI-Helper는 부적절한 답변을 할 수 있습니다.